Truist Securities Downgrades Amgen to Hold, Raises Price Target to $333
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has downgraded Amgen from Buy to Hold, while raising the price target from $320 to $333.
October 14, 2024 | 1:56 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Truist Securities has downgraded Amgen from Buy to Hold, indicating a more cautious outlook on the stock. However, the price target has been raised to $333, suggesting some positive expectations.
The downgrade from Buy to Hold suggests a less optimistic view on Amgen's short-term performance, which could lead to neutral or slightly negative sentiment. However, the raised price target to $333 indicates some underlying positive expectations, balancing the overall impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100